Roivant Sciences Ltd. (NASDAQ:ROIV) Q2 2024 Earnings Call Transcript
Q2 2024 Earnings Call Transcript November 12, 2024 Operator: Good day and thank you for standing by. Welcome to the Roivant Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Roivant Sciences Reports Q2 2024 Financial Results
Roivant Sciences Ltd. ( (ROIV) ) has released its Q2 earnings. Here is a breakdown of the information Roivant Sciences Ltd. presented to its
Q2 2024 Roivant Sciences Ltd Earnings Call
Good day and thank you for standing by. Welcome to the Roivant second-quarter 2024 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Stephanie Lee. Please go ahead.
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
Establishing growing body of preclinical data evaluating the DNase-based oncology platform across a number of high-value oncology indications
Marpai, Inc. Reports Q3 2024 Financial Results
Marpai, Inc. ( (MRAI) ) has released its Q3 earnings. Here is a breakdown of the information Marpai, Inc. presented to its investors. Marpai,
Discovery Reports Third Quarter 2024 Financial Results
Detailed price information for Discovery Silver Corp (DSV-T) from The Globe and Mail including charting and trades.
Finning reports Q3 2024 results
Finning International Inc. (TSX: FTT) ("Finning”, the "Company”, "we”, "our” or "us”) reported third quarter 2024 results today. All monetary amounts are in Canadian dollars unless otherwise stated. All comparisons are to Q3 2023 results unless indicated otherwise.
The Motley Fool1d
Roivant Sciences Posts Mixed Q2
Increased operational expenses and reduced cash reserves were cited. Roivant Sciences reports improved EPS for the second ...
Seeking Alpha8h
Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade)
Specifically, I will discuss the acquisition of Dermavant Sciences Ltd., a Roivant Sciences Ltd. (ROIV) company, with a ...
Who is Vivek Ramaswamy? Know about his early life, education, and role as head of the new "Department of Government Efficiency" (DOGE)
Indian-American entrepreneur and author Vivek Ramaswamy, known for founding Roivant Sciences, has become a prominent figure ...
Vivek Ramaswamy Net Worth: How Much Money Does the Co-Director of D.O.G.E Have?
Vivek Ramaswamy will lead, together with Elon Musk, the Department of Government Efficiency (D.O.G.E) in the Donald Trump ...
Seeking Alpha22d
Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility
Roivant's high valuation stems from its strong cash position, promising drug pipeline, Techbio assets, and strategic partnerships, making it a compelling buy. Recent sales of Telavant and ...
Roivant Sciences (ROIV) Receives a Buy from TD Cowen
TD Cowen analyst Yaron Werber maintained a Buy rating on Roivant Sciences (ROIV – Research Report) today. The company’s shares ...
The Business Journals29d
Biotech formed by Pfizer, Roivant eyes treatment for rare diseases
Priovant Therapeutics was formed in 2021 through a partnership between Roivant Sciences and Pfizer (NYSE: PFE) with a focus on developing new treatments for rare autoimmune diseases with high ...
Vivek Ramaswamy's journey from bright son of immigrants to being Donald Trump's pick
Vivek Ramaswamy, a biotech entrepreneur and former Republican presidential candidate, has been appointed by President-elect ...
Vivek Ramaswamy Net Worth: How this key Trump aide built his billion-dollar empire
Vivek Ramaswamy, 39, is a multimillionaire former biotech executive, who will lead the newly-established Department of ...